Dynamics of Cervical Cancer Diagnostic Market

The global cervical cancer diagnostic market size is calculated at US$ 5.08 billion in 2024, grew to US$ 5.37 billion in 2025, and is projected to reach around US$ 8.87 billion by 2034. The market is expanding at a CAGR of 5.74% between 2024 and 2034.

The rising incidences of cervical cancer, technological advancements, and favorable government policies drive the market.

Access the statistical data: https://www.towardshealthcare.com/download-statistics/5355

Cervical Cancer Diagnostic Market Trends

• The WHO’s Global Strategy aims to reduce the number of new cases annually to 4 or less per 100,000 women and sets three targets to be achieved by 2030:90% of girls vaccinated with the HPV vaccine by age 1570% of women screened with a high-quality test by ages 35 and 4590% of women with cervical disease receiving treatment
• In September 2024, the United States, Australia, India, and Japan launched Quad Cancer Moonshot to help end cancer in the Indo-Pacific, starting with cervical cancer. The efforts include improving healthcare infrastructure, expanding research collaborations, building data systems, and providing greater support for cancer prevention, detection, treatment, and care.
• In September 2024, DNA Wellness Pvt. Ltd. announced an investment of Rs 200 crore to establish 100 cervical cancer screening labs across India. The company had also secured the right to conduct the DNA Ploidy Test in India from the British Columbia Cancer Research Agency in Canada.

How Can AI Improve the Cervical Cancer Diagnostic Market?

Technological advancements have significantly improved the early diagnosis of cervical cancer. Integrating artificial intelligence (AI) in medical diagnostic applications can have excellent applicability in screening and diagnosing cervical cancer. Several organizations are developing AI-based methods to generate accurate results. AI and machine learning (ML) algorithms automatically recognize images, extract features, learn classification, and process data using complex algorithms. AI can reduce the time consumed for diagnosis and analysis of cervical cancer. It can also reduce the need for trained professionals to analyze test outcomes, thereby eliminating manual errors. In addition, AI can eliminate bias owing to subjective factors. AI can also aid in classifying the type and determining the stage of cervical cancer.

For instance,

• In September 2024, researchers from the Harvard Medical School developed a versatile, ChatGPT-like AI model to perform an array of diagnostic tasks for various cancers, including cervical cancer. The model can detect cancer cells and predict a tumor’s molecular profile.

Get the latest insights on healthcare industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

Market Dynamics

Driver

Increasing Incidences of Cervical Cancer

Cervical cancer is a major concern for women as it is the fourth most common cancer type globally. According to the WHO, around 660,000 new cases were reported in 2022, with around 350,000 deaths. More than 90% of the deaths are estimated to occur in low- and middle-income countries. The major cause of cervical cancer is HPV infection, a common sexually transmitted disease. The rising prevalence of HIV can also increase the risk of causing cervical cancer. Women living with HIV are 6 times more likely to develop cervical cancer compared to the general population, and an estimated 5% of all cervical cancer cases are attributable to HIV. Hence, the increasing incidences of cases demand early diagnosis and screening, boosting the cervical cancer diagnostic market.

Restraint

Lack of Awareness and High Cost

The cervical cancer diagnostic market faces formidable challenges, including a lack of awareness among women for early screening of the disease. Women, especially in developing countries, do not have sufficient knowledge about cervical cancer. Additionally, they have lack of access to information. Hence, several women are deprived of cancer diagnosis and screening. Another major challenge of the market is the relatively high cost of cervical cancer screening. The maximum average cost for initial screening, diagnostic tests, and follow-up is around $35,000 for 2 years in women younger than 21 years.

Opportunity

Growing Research and Development

The rising incidences of cervical cancer and favorable government initiatives to eliminate cervical cancer cases urge novel innovations for the diagnosis and treatment of the disease. The increasing investments drive research and development (R&D) in various research organizations. Some of the emerging techniques for cervical cancer prevention include liquid-based cytology, molecular testing, and AI. Therefore, the rapidly evolving genomics and proteomics research provides a breakthrough in cervical cancer diagnosis. Apart from these, point-of-care testing is also developed for the self-sampling of cervical cancer. The extended demand for point-of-care diagnostics also potentiates the cervical cancer diagnostic market. Several researchers conduct R&D to develop novel diagnostic methods to enhance the accuracy, efficiency, and cost-effectiveness of diagnostic testing.

For instance,

• In September 2023, scientists from the Montefiore Einstein Cancer Center developed a novel test for detecting cervical cancer by assessing HPV-16, 18, and 45 through methylation levels, providing a more accurate detection method.

Top Companies in the Cervical Cancer Diagnostic Market

• Abbott Laboratories
• Aptamer Group, plc
• Becton, Dickinson and Company
• Danaher Corporation
• F. Hoffman-La Roche Ltd.
• Guided Therapeutics, Inc.
• Healthians
• Hologic, Inc.
• MobileODT Ltd
• Novartis AG
• Quest Diagnostics
• Roche Diagnostics
• Timser Group

Latest Announcements by Industry Leaders

Matt Sause, CEO of Roche Diagnostics commented on the launch of its new HPV self-testing kit that the kit offers an accessible screening solution. He said that the WHO’s goal of eliminating cervical cancer can be achieved through vaccinations, innovative diagnostic tools, and screening programs. Their self-collection solution can reduce barriers and provide access to HPV screening.

Recent Developments in the Cervical Cancer Diagnostic Market

• In July 2024, researchers from the Waseda University, Kanazawa Medical University, and German Cancer Research Center developed a non-invasive alternative method to detect high-risk HPV16 E7 oncoproteins in urine using ELISA.
• In May 2024, Aptamer Group, plc announced a collaboration with Timser Group with a deal value of up to ￡465,000. The collaboration was made to develop the world’s first blood test for cervical cancer through Timser’s patented cervical cancer biomarker panel.

Acquire our comprehensive analysis today @ https://www.towardshealthcare.com/price/5355

You can place an order or ask any questions, please feel free to contact us at [email protected]

Browse our Brand-New Journals:

https://www.towardspackaging.com

https://www.towardsautomotive.com?

https://www.precedenceresearch.com

https://www.towardsdental.com

For Latest Update Follow Us: https://www.dhirubhai.net/company/towards-healthcare

Get Our Freshly Printed Chronicle:?https://www.healthcarewebwire.com